Patient reported outcomes among treatment modalities for prostate cancer

被引:0
|
作者
Johnson, Matthew E. [1 ]
Zaorsky, Nicholas G. [1 ]
Martin, Jeffrey M. [1 ]
Ruth, Karen [2 ]
Greenberg, Richard E. [3 ]
Uzzo, Robert G. [3 ]
Hayes, Shelly B. [1 ]
Smaldone, Marc C. [3 ]
Kutikov, Alexander [3 ]
Viterbo, Rosalia [3 ]
Chen, David Y. T. [3 ]
Hallman, Mark A. [1 ]
Sobczak, Mark L. [1 ]
Horwitz, Eric M. [1 ]
机构
[1] Fox Chase Canc Ctr, Dept Radiat Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Dept Biostat, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Urol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
关键词
sexual function; brachytherapy; prostate cancer; prostatectomy; radiation therapy; quality of life; comparative effectiveness research; personalized medicine; treatment selection; toxicity; genitourinary; gastrointestinal; QUALITY-OF-LIFE; DOSE-RATE BRACHYTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; CLINICAL TARGET VOLUME; RADIATION-THERAPY; RADICAL PROSTATECTOMY; CONSENSUS GUIDELINES; AMERICAN BRACHYTHERAPY; ADVANCED TECHNOLOGY; URINARY;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: To characterize patient reported outcomes for urinary and sexual function using International Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) comparing intensity modulated radiation therapy (IMRT), low dose rate brachytherapy (LDR), post-prostatectomy IMRT (PPRT), and radical prostatectomy (RP). Materials and methods: Patients treated for prostate cancer from 2001-2012 completed self-reported SHIM and IPSS surveys. Subgroups were created by baseline score. Mean change from baseline was determined at each time point for the cohort and subgroups. Statistical analysis was performed with generalized estimating equation method. Incontinence was not captured in the questionnaires. Results: A total of 14,523 IPSS surveys from 3,515 men were evaluated. Patients treated with IMRT experienced a minimal decrease in IPSS score from baseline. PPRT scores did not differ from IMRT at any time point (range: +1-3 points from baseline in IPSS score over 50 months). LDR had an initial IPSS rise (between 5-10 points on the IPSS over 1-9 months) versus IMRT but returned to comparable levels at 34 months. RP was associated with a lower IPSS versus IMRT. LDR had the largest rise from baseline, with return toward baseline. A total of 2,624 SHIM surveys from 857 men were evaluated. LDR and PPRT did not differ from IMRT at any time point (range: +1-5 points from baseline in SHIM score for 36 months). RP experienced the largest decline from baseline (up to -7 points on SHIM score), at 3 to 7 months; RP had a larger early decrease in SHIM score versus IMRT between 3 and 22 months, after which there was no difference. Conclusions: IPSS and SHIM score patterns differed among treatment modalities. These data can be used to predict changes in urinary and sexual function over time based on modality and baseline score.
引用
收藏
页码:8535 / 8545
页数:11
相关论文
共 50 条
  • [21] PROSTATE CANCER Patient-reported functional outcomes with radiation therapy
    Montgomery, Jeffrey S.
    NATURE REVIEWS UROLOGY, 2010, 7 (10) : 537 - 538
  • [22] NOVEL ELECTRONIC PATIENT REPORTED OUTCOMES TOOL FOR PROSTATE CANCER PATIENTS
    Aggarwal, S.
    Topaloglu, H.
    VALUE IN HEALTH, 2013, 16 (03) : A147 - A147
  • [23] PATIENT REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Aggarwal, S.
    Segal, J.
    Kumar, S.
    VALUE IN HEALTH, 2013, 16 (07) : A421 - A421
  • [24] Patient Reported Outcomes in Men Received Focal Therapy for Prostate Cancer
    Raheem, O. A.
    Maricano, O.
    Paruthi, M.
    JOURNAL OF SEXUAL MEDICINE, 2024, 21
  • [25] Treatment modalities for localised prostate cancer
    Abu-Ghanem, Yasmin
    Madhavan, Subash Guru
    Kirby, Roger
    Challacombe, Ben
    TRENDS IN UROLOGY & MENS HEALTH, 2012, 3 (02) : 21 - 25
  • [26] Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry
    Garin, O.
    Kowalski, C.
    Zamora, V.
    Roth, R.
    Ferrer, M.
    Breidenbach, C.
    Pont, A.
    Belin, T. R.
    Elashoff, D.
    Wilhalme, H.
    Nguyen, A. V.
    Kwan, L.
    Pearman, E. K.
    Bolagani, A.
    Sampurno, F.
    Papa, N.
    Moore, C.
    Millar, J.
    Connor, S. E.
    Villanti, P.
    Litwin, M. S.
    True North Global Registry
    BMC UROLOGY, 2023, 23 (01)
  • [27] Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry
    O. Garin
    C. Kowalski
    V. Zamora
    R. Roth
    M. Ferrer
    C. Breidenbach
    A. Pont
    T. R. Belin
    D. Elashoff
    H. Wilhalme
    A. V. Nguyen
    L. Kwan
    E. K. Pearman
    A. Bolagani
    F. Sampurno
    N. Papa
    C. Moore
    J. Millar
    S. E. Connor
    P. Villanti
    M. S. Litwin
    BMC Urology, 23
  • [28] The Europa Uomo Patient Reported Outcome Study 2.0-Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making
    Venderbos, Lionne D. F.
    Remmers, Sebastiaan
    Deschamps, Andre
    Dowling, John
    Carl, Ernst-Gunter
    Pereira-Azevedo, Nuno
    Roobol, Monique J.
    EUROPEAN UROLOGY FOCUS, 2023, 9 (06): : 1024 - 1036
  • [29] Patient-Reported Outcomes After Treatment for Lung Cancer
    Hill-Kayser, C. E.
    Vachani, C.
    Hampshire, M. K.
    Di Lullo, G. A.
    Metz, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S117 - S118
  • [30] Patient activation and patient-reported outcomes of men from a community pharmacy lifestyle intervention after prostate cancer treatment
    Lemanska, Agnieszka
    Poole, Karen
    Manders, Ralph
    Marshall, John
    Nazar, Zachariah
    Noble, Kevin
    Saxton, John M.
    Turner, Lauren
    Warner, Gary
    Griffin, Bruce A.
    Faithfull, Sara
    SUPPORTIVE CARE IN CANCER, 2022, 30 (01) : 347 - 358